Mangoceuticals (Mangoceuticals) Debt-to-Equity : -0.21 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Mangoceuticals Debt-to-Equity?

Mangoceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.15 Mil. Mangoceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.05 Mil. Mangoceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-0.96 Mil. Mangoceuticals's debt to equity for the quarter that ended in Mar. 2024 was -0.21.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Mangoceuticals's Debt-to-Equity or its related term are showing as below:

MGRX' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.29 Med: 0.09 Max: 0.58
Current: -0.21

During the past 3 years, the highest Debt-to-Equity Ratio of Mangoceuticals was 0.58. The lowest was -2.29. And the median was 0.09.

MGRX's Debt-to-Equity is not ranked
in the Healthcare Providers & Services industry.
Industry Median: 0.48 vs MGRX: -0.21

Mangoceuticals Debt-to-Equity Historical Data

The historical data trend for Mangoceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mangoceuticals Debt-to-Equity Chart

Mangoceuticals Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Equity

-2.29

0.58

0.17

Mangoceuticals Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial					0.07	0.05	0.11	0.17	-0.21

Competitive Comparison of Mangoceuticals's Debt-to-Equity

For the Health Information Services subindustry, Mangoceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mangoceuticals's Debt-to-Equity Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Mangoceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Mangoceuticals's Debt-to-Equity falls into.

Mangoceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Mangoceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.064	+	0.065)	/	0.775
	=	0.17

Mangoceuticals's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.153	+	0.048)	/	-0.958
	=	-0.21

Mangoceuticals (NAS:MGRX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Mangoceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Mangoceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Mangoceuticals (Mangoceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Mangoceuticals Inc (NAS:MGRX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

15110 N. Dallas Parkway, Suite 600, Dallas, TX, USA, 75248

Website

https://www.mangoceuticals.com

Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provide access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED product.

Executives

Amanda Elizabeth Hammer	officer: Chief Operating Officer	5128 GADSDEN AVENUE, KELLER TX 76244
Jacob D. Cohen	director, 10 percent owner, officer: CEO	2101 GLENDALE DRIVE, PLANO TX 75023
Tiger Cub Trust	10 percent owner	19 RYDDINGTON PL, DALLAS TX 75230
Kenny Myers	director	5101 ADDISON CIRCLE,, UNIT 401,, ADDISON TX 75001
Lorraine Pamela D'alessio	director	8200 WILSHIRE BLVD, BEVERLY HILLS, CALIFORNIA CA 90211
Eugene M Johnston	officer: CFO	PO BOX 669047, CHARLOTTE NC 28266
Jonathan Arango	director, officer: President, COO and Secretary	15110 DALLAS PARKWAY, SUITE 600, DALLAS TX 75248
Alex P. Hamilton	director	26 LOOP ROAD, BEDFORD NY 10506